$3250 | Single User
$4650 | Site License
$5650 | Global License

Kidney Cancer Market, by Therapeutic Class (Immunotherapy, Targeted Therapy), by Pharmacologic Class (Angiogenesis Inhibitors, Cytokine Immunotherapy, mTOR Inhibitors, Monoclonal Antibodies), and By Geography (NA, EU, APAC, LATAM and MEA) – Analysis, Share, Trends, Size, & Forecast from 2020 – 2026- COVID-19 Updated
[Lowest Price Guaranteed: $3,250]

Published by AnalystView: 01 Jun 2020 | 270613 | In Stock
Related Topics: Agencies , Antibodies , Cancer , Cytokine , Healthcare , Immunotherapy , Novartis , Pfizer , Roche

Introduction

REPORT HIGHLIGHT

Kidney cancer market was valued at USD 5.31 billion by 2019, growing with 5.1% CAGR during the forecast period, 2020-2026

Market Dynamics

Kidney cancer is among the most common cancer observed these days, which falls within the top ten most common cancer in both female and male. As per a study by the American Cancer Society (ACS), nearly 64,000 adults are diagnosed with kidney cancer every year in the U.S. of which about 64% are male. In addition, the average age of diagnosis is 64 years and above. Thus, growing prevalence of kidney cancer owing to adoption of unhealthy lifestyles such as less physical activity, drinking, and smoking and approval of novel drugs for treatment are the major factors driving the growth of global kidney cancer drugs market.

In addition, immunotherapies would arise as an opportunity for innovators in the market. Furthermore, a huge number of the undiagnosed patient base in the untapped geographies will likely create lucrative opportunities for the market vendors. However, increasing preference for generic drugs and high costs associated with branded drugs to treat cancer are expected to hamper the market growth in the coming future.

Segment Takeaway

Targeted therapy will be high in demand owing to the rising preference of immune-oncologic agents and novel immunotherapies. Several forms of cancer treatment methods have been instigated amongst the currently approved drugs such as cytokine therapy, immune modulation therapy, mTOR inhibitor, and VEGF inhibitor. Thus, the targeted therapy segment is estimated to hold the largest market share in the projected timeframe. In addition, it is also predicted that the combination regiments of PD-1 inhibitors will be introduced in the first place to target major unmet needs such as maintaining the quality of life, enhancing progression-free survival, and overcoming tumour resistance.

The drug development for kidney cancer focuses on using novel treatments as kidney cancer is not responsive to traditional treatments of cancer treatments. PD-L1 and PD-1 inhibitors represent a model shift in the treatment of kidney cancer. Several PD-L1 and PD-1 agents with fresh MoAs are in early stages of development and are being estimated both as monotherapy and with immune-oncology agents that are already approved. Thus, it is estimated that mTOR inhibitors will be the fastest-growing segment during the forecast period.

Regional Takeaway

Presently, the North America region is estimated to subjugate the global kidney cancer drugs market trailed by Europe and the Asia Pacific. Presence of large patient pool & major market vendors and well-established healthcare infrastructure is driving the growth of North America kidney cancer drugs market. On the other hand, growing prevalence of kidney cancer and increasing government initiatives to enhance healthcare facilities in the developing economies of Asia Pacific will help the region to grow at the fastest rate during the forecast period.

In kidney cancer therapeutics, biosimilar development is gaining popularity as a promising market opportunity. The prominent players of the industry are adopting several strategies such as commercial expansion, clinical collaborations, and novel product development to increase their market share. These players functioning in the global market include:

• Bayer Healthcare

• Novartis AG

• Prometheus Labs

• Eisai Co., Ltd.

• Bristol-Myers Squibb

• Genentech (Roche)

• Exelixis

• Pfizer, Inc.

The market size and forecast for each segment and sub-segments has been considered as below:

• Historical Year – 2015 to 2018

• Base Year – 2019

• Estimated Year – 2020

• Projected Year – 2026

TARGET AUDIENCE

 Traders, Distributors, and Suppliers

 Manufacturers

 Government and Regional Agencies

 Research Organizations

 Consultants

 Distributors

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL KIDNEY CANCER MARKET, BY THERAPEUTIC CLASS

 Targeted Therapy

 Immunotherapy

 Others

GLOBAL KIDNEY CANCER MARKET, BY PHARMACOLOGICAL CLASS

 Cytokine Immunotherapy (IL-2)

 Angiogenesis Inhibitors

 Mammalian Target of Rapamycin (mTOR) Inhibitors

 Monoclonal Antibodies

 Others

GLOBAL KIDNEY CANCER MARKET, BY REGION

 North America

o The U.S.

o Canada

 Europe

o Germany

o France

o Italy

o Spain

o United Kingdom

o Rest of Europe

 Asia Pacific

o India

o China

o South Korea

o Japan

o Singapore

o Rest of APAC

 Latin America

o Brazil

o Mexico

o Argentina

o Rest of LATAM

 Middle East and Africa

o Saudi Arabia

o United Arab Emirates

o Rest of MEA

Table of Contents
for Kidney Cancer Market, by Therapeutic Class (Immunotherapy, Targeted Therapy), by Pharmacologic Class (Angiogenesis Inhibitors, Cytokine Immunotherapy, mTOR Inhibitors, Monoclonal Antibodies), and By Geography (NA, EU, APAC, LATAM and MEA) – Analysis, Share, Trends, Size, & Forecast from 2020 – 2026- COVID-19 Updated

  • TABLE OF CONTENT

    1. KIDNEY CANCER DRUGS MARKET OVERVIEW

    1.1. Study Scope

    1.2. Assumption and Methodology

    2. EXECUTIVE SUMMARY

    2.1. Market Snippet

    2.1.1. Market Snippet by Therapeutic Class

    2.1.2. Market Snippet by Pharmacological Class

    2.1.3. Market Snippet by Region

    2.2. Competitive Insights

    3. KIDNEY CANCER DRUGS KEY MARKET TRENDS

    3.1. Market Drivers

    3.1.1. Impact Analysis of Market Drivers

    3.2. Market Restraints

    3.2.1. Impact Analysis of Market Restraints

    3.3. Market Opportunities

    3.4. Market Future Trends

    4. KIDNEY CANCER DRUGS INDUSTRY STUDY

    4.1. Porter’s Five Forces Analysis

    4.2. Marketing Strategy Analysis

    4.3. Growth Prospect Mapping

    4.4. Regulatory Framework Analysis

    4.5. COVID-19 Impact Analysis

    4.5.1. Pre-COVID-19 Impact Analysis

    4.5.2. Post-COVID-19 Impact Analysis

    5. KIDNEY CANCER DRUGS MARKET LANDSCAPE

    5.1. Market Share Analysis

    5.2. Key Innovators

    5.3. Breakdown Data, by Key manufacturer

    5.3.1. Established Player Analysis

    5.3.2. Emerging Player Analysis

    6. KIDNEY CANCER DRUGS MARKET – BY THERAPEUTIC CLASS

    6.1. Overview

    6.1.1. Segment Share Analysis, By Therapeutic Class, 2019 & 2026 (%)

    6.2. Targeted Therapy

    6.2.1. Overview

    6.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

    6.3. Immunotherapy

    6.3.1. Overview

    6.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

    6.4. Others

    6.4.1. Overview

    6.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

    7. KIDNEY CANCER DRUGS MARKET – BY PHARMACOLOGICAL CLASS

    7.1. Overview

    7.1.1. Segment Share Analysis, By Pharmacological Class, 2019 & 2026 (%)

    7.2. Cytokine Immunotherapy (IL-2)

    7.2.1. Overview

    7.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

    7.3. Angiogenesis Inhibitors

    7.3.1. Overview

    7.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

    7.4. Mammalian Target of Rapamycin (mTOR) Inhibitors

    7.4.1. Overview

    7.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

    7.5. Monoclonal Antibodies

    7.5.1. Overview

    7.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

    7.6. Others

    7.6.1. Overview

    7.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

    8. KIDNEY CANCER DRUGS MARKET– BY GEOGRAPHY

    8.1. Introduction

    8.1.1. Segment Share Analysis, By Region, 2019 & 2026 (%)

    8.2. North America

    8.2.1. Overview

    8.2.2. Key Manufacturers in North America

    8.2.3. North America Market Size and Forecast, By Country, 2015 - 2026 (US$ Million)

    8.2.4. North America Market Size and Forecast, By Therapeutic Class, 2015 - 2026 (US$ Million)

    8.2.5. North America Market Size and Forecast, By Pharmacological Class, 2015 - 2026 (US$ Million)

    8.2.6. U.S.

    8.2.6.1. Overview

    8.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

    8.2.7. Canada

    8.2.7.1. Overview

    8.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

    8.3. Europe

    8.3.1. Overview

    8.3.2. Key Manufacturers in Europe

    8.3.3. Europe Market Size and Forecast, By Country, 2015 - 2026 (US$ Million)

    8.3.4. Europe Market Size and Forecast, By Therapeutic Class, 2015 - 2026 (US$ Million)

    8.3.5. Europe Market Size and Forecast, By Pharmacological Class, 2015 - 2026 (US$ Million)

    8.3.6. Germany

    8.3.6.1. Overview

    8.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

    8.3.7. Italy

    8.3.7.1. Overview

    8.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

    8.3.8. United Kingdom

    8.3.8.1. Overview

    8.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

    8.3.9. France

    8.3.9.1. Overview

    8.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

    8.3.10. Rest of Europe

    8.3.10.1. Overview

    8.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

    8.4. Asia Pacific (APAC)

    8.4.1. Overview

    8.4.2. Key Manufacturers in Asia Pacific

    8.4.3. Asia Pacific Market Size and Forecast, By Country, 2015 - 2026 (US$ Million)

    8.4.4. Asia Pacific Market Size and Forecast, By Therapeutic Class, 2015 - 2026 (US$ Million)

    8.4.5. Asia Pacific Market Size and Forecast, By Pharmacological Class, 2015 - 2026 (US$ Million)

    8.4.6. India

    8.4.6.1. Overview

    8.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

    8.4.7. China

    8.4.7.1. Overview

    8.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

    8.4.8. Japan

    8.4.8.1. Overview

    8.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

    8.4.9. South Korea

    8.4.9.1. Overview

    8.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

    8.4.10. Rest of APAC

    8.4.10.1. Overview

    8.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

    8.5. Latin America

    8.5.1. Overview

    8.5.2. Key Manufacturers in Latin America

    8.5.3. Latin America Market Size and Forecast, By Country, 2015 - 2026 (US$ Million)

    8.5.4. Latin America Market Size and Forecast, By Therapeutic Class, 2015 - 2026 (US$ Million)

    8.5.5. Latin America Market Size and Forecast, By Pharmacological Class, 2015 - 2026 (US$ Million)

    8.5.6. Brazil

    8.5.6.1. Overview

    8.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

    8.5.7. Mexico

    8.5.7.1. Overview

    8.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

    8.5.8. Argentina

    8.5.8.1. Overview

    8.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

    8.5.9. Rest of LATAM

    8.5.9.1. Overview

    8.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

    8.6. Middle East and Africa

    8.6.1. Overview

    8.6.2. Key Manufacturers in Middle East and Africa

    8.6.3. Middle East and Africa Market Size and Forecast, By Country, 2015 - 2026 (US$ Million)

    8.6.4. Middle East and Africa Market Size and Forecast, By Therapeutic Class, 2015 - 2026 (US$ Million)

    8.6.5. Middle East and Africa Market Size and Forecast, By Pharmacological Class, 2015 - 2026 (US$ Million)

    8.6.6. Saudi Arabia

    8.6.6.1. Overview

    8.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

    8.6.7. United Arab Emirates

    8.6.7.1. Overview

    8.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

    9. KEY VENDOR ANALYSIS

    9.1. Bayer Healthcare

    9.1.1. Company Snapshot

    9.1.2. Financial Performance

    9.1.3. Product Benchmarking

    9.1.4. Strategic Initiatives

    9.2. Novartis AG

    9.3. Prometheus Labs

    9.4. Eisai Co., Ltd.

    9.5. Bristol-Myers Squibb

    9.6. Genentech (Roche)

    9.7. Exelixis, Inc.

    9.8. Pfizer, Inc.

    10. 360 DEGREE ANALYSTVIEW

    11. APPENDIX

    11.1. Research Methodology

    11.2. References

    11.3. Abbreviations

    11.4. Disclaimer

    11.5. Contact Us

List Of Tables
in Kidney Cancer Market, by Therapeutic Class (Immunotherapy, Targeted Therapy), by Pharmacologic Class (Angiogenesis Inhibitors, Cytokine Immunotherapy, mTOR Inhibitors, Monoclonal Antibodies), and By Geography (NA, EU, APAC, LATAM and MEA) – Analysis, Share, Trends, Size, & Forecast from 2020 – 2026- COVID-19 Updated

List of Tables

TABLE List of data sources

TABLE Market drivers; Impact Analysis

TABLE Market restraints; Impact Analysis

TABLE Kidney Cancer Drugs market: Therapeutic Class Snapshot (2018)

TABLE Segment Dashboard; Definition and Scope, by Therapeutic Class

TABLE Global Kidney Cancer Drugs market, by Therapeutic Class 2015-2026 (USD Million)

TABLE Kidney Cancer Drugs market: Pharmacological Class Snapshot (2018)

TABLE Segment Dashboard; Definition and Scope, by Pharmacological Class

TABLE Global Kidney Cancer Drugs market, by Pharmacological Class 2015-2026 (USD Million)

TABLE Kidney Cancer Drugs market: Regional snapshot (2018)

TABLE Segment Dashboard; Definition and Scope, by Region

TABLE Global Kidney Cancer Drugs market, by Region 2015-2026 (USD Million)

TABLE North America Kidney Cancer Drugs market, by Country, 2015-2026 (USD Million)

TABLE North America Kidney Cancer Drugs market, by Therapeutic Class, 2015-2026 (USD Million)

TABLE North America Kidney Cancer Drugs market, by Pharmacological Class, 2015-2026 (USD Million)

TABLE Europe Kidney Cancer Drugs market, by country, 2015-2026 (USD Million)

TABLE Europe Kidney Cancer Drugs market, by Therapeutic Class, 2015-2026 (USD Million)

TABLE Europe Kidney Cancer Drugs market, by Pharmacological Class, 2015-2026 (USD Million)

TABLE Asia Pacific Kidney Cancer Drugs market, by country, 2015-2026 (USD Million)

TABLE Asia Pacific Kidney Cancer Drugs market, by Therapeutic Class, 2015-2026 (USD Million)

TABLE Asia Pacific Kidney Cancer Drugs market, by Pharmacological Class, 2015-2026 (USD Million)

TABLE Latin America Kidney Cancer Drugs market, by country, 2015-2026 (USD Million)

TABLE Latin America Kidney Cancer Drugs market, by Therapeutic Class, 2015-2026 (USD Million)

TABLE Latin America Kidney Cancer Drugs market, by Pharmacological Class, 2015-2026 (USD Million)

TABLE Middle East and Africa Kidney Cancer Drugs market, by country, 2015-2026 (USD Million)

TABLE Middle East and Africa Kidney Cancer Drugs market, by Therapeutic Class, 2015-2026 (USD Million)

TABLE Middle East and Africa Kidney Cancer Drugs market, by Pharmacological Class, 2015-2026 (USD Million)

List Of Figures, Charts and Diagrams
in Kidney Cancer Market, by Therapeutic Class (Immunotherapy, Targeted Therapy), by Pharmacologic Class (Angiogenesis Inhibitors, Cytokine Immunotherapy, mTOR Inhibitors, Monoclonal Antibodies), and By Geography (NA, EU, APAC, LATAM and MEA) – Analysis, Share, Trends, Size, & Forecast from 2020 – 2026- COVID-19 Updated

List of Figures

FIGURE Kidney Cancer Drugs market segmentation

FIGURE Market research methodology

FIGURE Value chain analysis

FIGURE Porter’s Five Forces Analysis

FIGURE Market Attractiveness Analysis

FIGURE COVID-19 Impact Analysis

FIGURE Pre & Post COVID-19 Impact Comparision Study

FIGURE Competitive Landscape; Key company market share analysis, 2018

FIGURE Therapeutic Class segment market share analysis, 2019 & 2026

FIGURE Therapeutic Class segment market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Targeted Therapy segment market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Immunotherapy segment market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Pharmacological Class segment market share analysis, 2019 & 2026

FIGURE Pharmacological Class segment market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Cytokine Immunotherapy (IL-2) segment market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Angiogenesis Inhibitors segment market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Mammalian Target of Rapamycin (mTOR) Inhibitors segment market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Monoclonal Antibodies segment market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Regional segment market share analysis, 2019 & 2026

FIGURE Regional segment market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE North America Kidney Cancer Drugs market share and leading players, 2018

FIGURE Europe Kidney Cancer Drugs market share and leading players, 2018

FIGURE Asia Pacific Kidney Cancer Drugs market share and leading players, 2018

FIGURE Latin America Kidney Cancer Drugs market share and leading players, 2018

FIGURE Middle East and Africa Kidney Cancer Drugs market share and leading players, 2018

FIGURE North America Kidney Cancer Drugs market share analysis by country, 2018

FIGURE U.S. Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Canada Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Europe Kidney Cancer Drugs market share analysis by country, 2018

FIGURE Germany Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Spain Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Italy Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE UK Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE France Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Rest of the Europe Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Asia Pacific Kidney Cancer Drugs market share analysis by country, 2018

FIGURE India Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE China Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Japan Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE South Korea Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Singapore Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Rest of APAC Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Latin America Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Latin America Kidney Cancer Drugs market share analysis by country, 2018

FIGURE Brazil Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Mexico Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Argentina Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Rest of LATAM Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Middle East and Africa Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Middle East and Africa Kidney Cancer Drugs market share analysis by country, 2018

FIGURE Saudi Arabia Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE United Arab Emirates Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

Additional Details

Publisher

AnalystView

Publisher Information

AnalystView Market Insights is a market research and consulting firm that adopts a proactive approach to provide the diverse need for accurate and precise market research, custom research, and consulting solutions across geographies and industry verticals. Our company is led by a team of passionate, naturally curious, and strategic thinkers from different industry backgrounds.



These experts are dedicated to creating concrete market data analysis in various industries such as Healthcare, Bulk Chemicals, Semiconductors and Electronics, Foods and Beverages. We strive to develop meaningful and evidence-based research data that helps our clients, empowering organizations and brands of all sizes with strategic analysis, accurate data, and consumer trends.



We aim to be the number one choice for various clients who require credible data to make vital business decisions. We wish to be a trusted and reliable analytics partner to major business organizations.



We understand that critical business decisions can be taken only when verified, authentic information is available. Therefore, our experts work meticulously to provide our clients with the accurate data, so that they need not spend time in verifying it.



It is also our goal to help our clients ignore traditional research methods that require a large amount of capital, manpower, and most important of it all – the time. We know that these factors are precious to a company and always follow the latest research techniques that produce the required result in a short span of time.

Reference

270613 | AV89

Number of Pages

180

Report Format

PDF

AnalystView Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Chronic Kidney Disease Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Nov 2016 by Current Partnering USD $1,495 More Info
Global Chronic Kidney Disease Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Kidney Transplant Rejection Global Clinical Trials Review, H2, 2016
Kidney Transplant Rejection Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical tria...
30 Sep 2016 by Global Data USD $2,500 More Info
Urology Surgical Instruments Market by Product (Endoscopes, Endovision Systems, Peripheral Instruments, Consumables and Accessories), Application (Chronic Kidney Diseases, Benign Prostatic Hyperplasia, Oncology) - Global Forecast to 2021
The global urology surgical instruments market is expected to reach USD 11.48 billion by 2021 from U...
01 Sep 2016 by MarketsandMarkets USD $5,650 More Info
Organ-on-Chip Global Market 2010-2020 Including: Lung-on-chip, Heart-on-chip, Liver-on-chip, Intestine-on-chip, Kidney-on-chip and Human-on-chip, Human disease and tissue models, Microfluidics Historic and Forecast 2010 – 2020 Covering: North America, Europe, Rest Of World (ROW)
Organ-on-chips or organ-on-a-chips (OOCs) are microfluidic 3D cell culture devices that closely mimi...
30 May 2016 by The Business Research Company USD $4,000 More Info
Hospitals and Outpatient Care Centers Global Market Analytics Report 2016 Including: Freestanding Ambulatory Surgical and Emergency Centers, General Medical and Surgical Hospitals, HMO Medical Centers, All Other Outpatient Care Centers, Kidney Dialysis Centers Historic and Forecast Growth Rate 2011 – 2019 Analysing: Expenditure Per Capita, Expenditure Per Household, Government Expenditure, Healt
The Hospitals and Outpatient Care Centers Market Analytics Report provides strategists, marketers an...
23 May 2016 by The Business Research Company USD $2,000 More Info
Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H1, 2016
Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H1, 2016SummaryGlobal...
20 Apr 2016 by Global Data USD $2,500 More Info
Hyperphosphatemia In Chronic Kidney Disease Global Clinical Trials Review, H2, 2015
Hyperphosphatemia In Chronic Kidney Disease Global Clinical Trials Review, H2, 2015SummaryGlobalData...
25 Nov 2015 by Global Data USD $2,500 More Info
Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Review, H2, 2015
Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Review, H2, 2015SummaryGlobalD...
30 Oct 2015 by Global Data USD $2,500 More Info
Chronic Kidney Disease - Pipeline Analysis
“Chronic Kidney Disease (CKD) Pipeline Analysis” gives comprehensive insight on the various drugs be...
07 May 2015 by IQ4I USD $3,600 More Info

This report is published by AnalystView

AnalystView Market Insights is a market research and consulting firm that adopts a proactive approach to provide the diverse need for accurate and precise market research, custom research, and consulting solutions across geographies and industry verticals. Our company is led by a team of passionate, naturally curious, and strategic thinkers from different industry backgrounds.

These experts are dedicated to creating concrete market data analysis in various industries such as Healthcare, Bulk Chemicals, Semiconductors and Electronics, Foods and Beverages. We strive to develop meaningful and evidence-based research data that helps our clients, empowering organizations and brands of all sizes with strategic analysis, accurate data, and consumer trends.

We aim to be the number one choice for various clients who require credible data to make vital business decisions. We wish to be a trusted and reliable analytics partner to major business organizations.

We understand that critical business decisions can be taken only when verified, authentic information is available. Therefore, our experts work meticulously to provide our clients with the accurate data, so that they need not spend time in verifying it.

It is also our goal to help our clients ignore traditional research methods that require a large amount of capital, manpower, and most important of it all – the time. We know that these factors are precious to a company and always follow the latest research techniques that produce the required result in a short span of time.

Download Free Report Summary PDF

Kidney Cancer Market, by Therapeutic Class (Immunotherapy, Targeted Therapy), by Pharmacologic Class (Angiogenesis Inhibitors, Cytokine Immunotherapy, mTOR Inhibitors, Monoclonal Antibodies), and By Geography (NA, EU, APAC, LATAM and MEA) – Analysis, Share, Trends, Size, & Forecast from 2020 – 2026- COVID-19 Updated | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...